89Zr-Patritumab deruxtecan

89Zr-德帕瑞妥单抗

Report date: 2026/05/06 20:02:28
First In Class

Base Information

Drug Name89Zr-Patritumab deruxtecan
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products > Radioactive diagnostic agent +[6] 
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsDNA topoisomerase I inhibitors
TargetsReceptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co LtdThe Netherlands Cancer InstituteDaiichi Sankyo Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Netherlands Cancer InstituteDaiichi Sankyo Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A